Japanese drugmaker Otsuka Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted for review the ...

Anthem Biosciences files for a $397 million IPO amid India’s record-breaking year for public listings. The Bengaluru-based ...

Alon Natanson, a business leader and alumnus of the Hebrew University of Jerusalem, has been appointed chief executive ...

Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.

China’s National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of Dovbleron ...

Californian biotech General Proximity announced its emergence from stealth on Friday, unveiling its proprietary OmniTAC ...

"A dynamic and versatile pharmaceutical company with regional horizons in Latin America." "Axon Pharma is an independent multinational pharmaceutical company built on high-standards science and ...

Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

PrimeGene raises $46 million in a series B round to advance Phase III trials and regulatory filings for pumecitinib, its atopic dermatitis treatment. Funds will also support pipeline expansion and IPO ...

WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...

Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – ...